Human papillomavirus vaccine does not appear to negatively affect pregnancy
Researchers reviewed data on women exposed to an HPV vaccine up to 1 month prior to onset of their last menstrual period or at any time during pregnancy.
Researchers reviewed prospective data on 517 women from the United States, France, and Canada who were exposed to the human papillomavirus (HPV) type 6/11/16/18 vaccine up to 1 month before the onset of their last menstrual period or at any time during pregnancy.
Of these women, 451 had live births, including 3 sets of twins, for a total of 454 neonates. Overall rates of spontaneous abortion, major birth defects, and fetal death were 6.9 per 100 outcomes (95% confidence interval [CI], 4.8-9.6), 2.2 per 100 liveborn neonates (95% CI, 1.05-4.05), and 1.5 per 100 outcomes (95% CI, 0.60-3.09), respectively. All of the rates were no greater than those in unexposed populations.
Dana A, Buchanan K, Goss MA, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol. 2009;114(6):1170-1178.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
